The top 5 cybersecurity threats to pharma for 2022

In the realm of DNA sequencing, technology developers contribute to advancement in important ways, by building increasingly fast-moving tools that untangle the intricacies of the human genome, and by constructing analytics platforms to wade through the resulting mountains of genetic data.

This talk presents an overview of the philosophy and ongoing work of the PhUSE project "Clinical Trials Results as Resource Description Framework." The team is converting data from the CDISC Study Data Tabulation Model (SDTM) to graph data using an ontology-based approach. The wider implications of this work are discussed, along with deployment strategies within and beyond the industry.

The science of medicine has allowed us to make incredible advances in diagnosing and treating diseases. But the complexity of human biology is staggering. Every person is unique and in many ways, so are diseases. Yet the digital revolution in healthcare provides new ways to both collect high-quality data from each patient and connect it to data from large pools of other patients for analysis. This enables us to arrive at a deeper understanding of how to treat an individual. Only then can we see what distinguishes each of us as individuals, and translate that into personalized and thus improved care for every person. Real-world evidence, molecular information generated from next-generation sequencing, data from wearable devices and mobile apps and novel clinical trials are transforming the future of care.

Countries around the world continue to add serialization and track-and-trace requirements. Additionally, countries that have already reached compliance deadlines continue to modify future timelines and conditions, creating uncertainty.